Activities

PHRG Activities

2019 - Pulmonary Vascular Research Institute

Barcelona, Spain

The 13th annual congress of Pulmonary Vascular Research Institute took place from January 30th to February 3rd 2019 in Barcelona, Spain. Some members of the research group presented their research project and share their knowledge in Pulmonary Hypertension pathogenesis with other researchers.

During this congress, some team members and ex-member received distinction and awards. Our fellowship trainee Junichi Omura received a Presentation award in category Fellow for his project on lncH19; Dr Roxane Paulin received a Travel award and a Presentation award in young investigator category; Dr Olivier received the Abstract/Poster young investigator; Finally Drs Sébastien Bonnet and Steeve Provencher were honored with a recognition award of scientific program chair.

We want also to emphasize that Dr François Potus, alumni of our research group, received the Rupert Swift award, a newly established PVRI Grant to support a young, promising researcher in pulmonary vascular diseases field.

Congratulations!

Congrès Texte alt

2018 - American Heart Association

Chicago, IL, United States of America

American heart Association congress took place from November 10-12th 2018, Chicago (IL). Some members of the research group presented their research project and share their knowledge on Pulmonary Hypertension field with other international researchers.

After getting Cardiopulmonary best abstract Award from AHA 3CPR Council, Dr Junichi Omura obtained one of the famous AHA’ famous price, the 2018 Paul Dudley White International Scholar. This price recognizes the Authors with the highest rank abstract from all Canada’ submissions at scientific sessions 2018. This congress is the largest meeting of cardiovascular experts in the world, involving tens of thousands of people every year.

We would also like to emphasize that Karima Habbout and Alice Bourgeois, students under supervision of Dr Boucherat, received a Travel Award to present their research project in this congress.

In addition to these good news, our research group participated in obtaining the abstract of Netherlands submitted to AHA. Indeed, our research group with Netherlands’ PH consortium, demonstrated that BRD4 protein inhibition improves PAH. This work, initiated by Dre Meloche (alumni), was deepened by Eve Tremblay (research assistant) an by our colleagues from Netherlands. All of this work has led to the setting up of a clinical trial at IUCPQ under direction of Drs Provencher and Bonnet.

2018 - European Respiratory Society

Paris, France

European Respiratory Society congress took place from September 15th-19th 2018, Paris (France).

Some members of the research group presented their research project and share their knowledge on Pulmonary Hypertension field with other international researchers.

In addition, some alumni of the research group shared some time together to… feast!

2018 - American Thoracic Society

San Diego, CA, United States of America

American Thoracic Society congress took place from May 18th-23rd 2018, San Diego (CA).

Some members of the research group presented their research project and share their knowledge on Pulmonary Hypertension field with other international researchers.

In addition, members gathered took the opportunity to realize a 10km race in order to realize their personal challenge to ” À plein poumon pour l’HTAP!”, that will take place in October 2018.

2017 - American Heart Association

Anaheim, CA, United States of America

American Heart Association congress took place from November 11th-14th 2017, Anaheim (CA).  Some members of the research group presented their research project and share their knowledge on Pulmonary Hypertension field.

2019

December 2, 2019

Interview with Dr Sébastien Bonnet by the WSPHA
WSPHA (World Symposia on Pulmonary Hypertension Association) and precision medicine for PH. An interview with Prof. Sebastien Bonnet, acting director of the Pulmonary Hypertension research group at the Lung and Heart Institute of Quebec City and member of the WSPHA Scientific Board

June 14, 2019

Research on pulmonary arterial hypertension at the Institute
Pulmonary arterial hypertension (PAH) is an unrecognized and incurable disease. For 10 years, the PAH Research Group has maintained its unrelenting efforts to treat this disease. He has just received funding of $ 3.2 million to test a drug that would prevent the development of the disease.

June 3, 2019

Pulmonary arterial hypertension: new study gives hope
Pulmonary arterial hypertension is a serious disease that has not yet been treated. The Institute will lead a new study to test a drug, giving patients hope. This report is courtesy of ICI Radio-Canada Quebec.

May 30, 2019

PAH: First Global Study in Epigenetics to Treat this Disease
On the margins of the World Pulmonary Arterial Hypertension Day, the Quebec Heart and Lung Institute – Laval University (the Institute) is proud to announce the establishment of the first global study in epigenetics on the treatment of pulmonary arterial hypertension (PAH).

To better treat pulmonary arterial hypertension
The Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval is launching a large epigenetic study on the treatment of this disease

A new drug against pulmonary arterial hypertension Pulmonary
Arterial hypertension, a little-known disease, affects at least 2,000 Quebecers. There is no cure for this rare disease, which can be fatal within a few years. But a new study on a drug, launched by the University Institute of Cardiology and Pneumology of Quebec, gives hope. Nicole Germain’s report.

2016

May 20, 2016

Combination Therapy Improves Pulmonary Hypertension Outcomes
For patients with pulmonary arterial hypertension, combination therapy reduces the risk of clinical worsening better than monotherapy, a new meta-analysis indicates. An interview with Dr S. Provencher MD, from Laval University in Quebec City, Canada, by Damian McNamara

2014

May 9, 2014

Pulmonary hypertension – diagnostic delays are long
A patient testifies and Dr Steeve Provencher explains. Courtesy of ICI Radio-Canada Télé.

May 5, 2014

Pulmonary hypertension
Dr Steeve Provencher, pulmonologist at the IUCPQ and eminent specialist in pulmonary hypertension, answers various questions, in particular: What is pulmonary hypertension? What are the symptoms? Who is at risk? What are the treatments? Courtesy of the Pulmonary Hypertension Association of Canada (AHPC)

2013

February 27, 2013

Video on pulmonary arterial hypertension by Dr Bonnet
Dr Pierre Bonnet, cardiologist and pulmonologist, explains pulmonary arterial hypertension.

2012

May 3, 2012

When winter hits the lungs
Interview given by Dr Steeve Provencher to the newspaper Le Soleil

April 30, 2012

Interview given by Dr Provencher for the Faculty of Medicine of Laval University
Professor in the Department of Medicine at Laval University and researcher at the Research Center of the University Institute of Cardiology and Pneumology of Quebec (CRIUCPQ), Steeve Provencher wishes finding a cure for pulmonary arterial hypertension.

February 21, 2012

Important discovery of the pulmonary hypertension research group
Interview with Drs. Steeve Provencher and Sébastien Bonnet from the research center of the University Institute of Cardiology and Pneumology of Quebec as well as with Ms Micheline Richard, patient. A report by Nicole Germain for Radio-Canada.

New discoveries in pulmonary arterial hypertension
Dr Sébastien Bonnet talks about pulmonary hypertension on the program “Retour sur le monde” on Radio-Canada radio

Anti-cancer drugs would be effective
Four Quebec researchers have made an astonishing discovery. These researchers from Laval Hospital and CHUQ found that certain drugs against breast, ovarian or colon cancer could also treat pulmonary hypertension. Interview given by Dr Steeve Provencher for TVA Nouvelles.

2010

October 24, 2010

Quebec researchers pave the way for an innovative treatment of pulmonary hypertension
Report published by the Heart and Stroke Foundation of Canada

August 12, 2010

Pulmonary arterial hypertension explained
Popular article based on the publication of a scientific article by the PAH research group in the journal Science Translational Medicine

2019 - À pleins poumons pour l'HTAP!

Québec, Canada

For the fourth year in a row, it was on October 13, 2019 that our research group took up the challenge “À pleins poumons pour l’HTAP!”. The courageous runners covered the 10km or 21.1km distances of the SSQ Insurance Quebec City Marathon, an invitation from Santé Brunet.

We raised the sum of $ 54,000 thanks to:

  • our valued partners:
    HVL Therapeutique, Resverlogix, Johnson & Johnson, Pharmacie Michael Assaraf
  • the sale of African violets, courtesy of students in Laboratory Techniques from Cégep de Lévis-Lauzon
  • the sale of handmade soap from Sapora
  • all personal donations

These funds are dedicated to contributing to the development of research in PAH and to improving the quality of life of patients affected by the disease.

2018 - À pleins poumons pour l'HTAP!

Québec, Canada

October 14th 2018 took place the third edition of the challenge ”À pleins poumons pour l’HTAP!”, where 11 members of Pulmonary arterial research Group have been challenged to a running of 10 or 21 km during the SSQ Québec marathon to support advance in PAH research.

Thanks to  the support of population and different partners. With IUCPQ Foundation partnership, this fund raising will allow to come in assistance to people present sick and those will be in the future. Amassed funds will be used to advance the search in order to develop the therapies of the future and to offer cutting edge care to patients suffering from PAH.

2017 - À pleins poumons pour l'HTAP!

Québec, Canada

August 27th 2017 has taken place the second edition of the challenge “À pleins poumons pour l’HTAP!”, where 20 members of Pulmonary arterial research group were challenged to support the people affected by this grave disease. A running of 10km or 21km has been done during SSQ Levis marathon to raise awareness and make sensitive the population to this disease.

With the support of population and different partners especially Bayer Canada, we are proud to announce that we collected 9000$. With IUCPQ Foundation partnership, this fund raising will allow to come in assistance to people present sick and those will be in the future. Amassed funds will be used to advance the search in order to develop the therapies of the future and to offer cutting edge care to patients suffering from PAH.

2016 - À pleins poumons pour l'HTAP!

Québec, Canada

On August 28, 2016, the first edition of the challenge “À pleins poumons pour l’HTAP!” took place, where 17 members of the Pulmonary Arterial Hypertension Research Group (PAH) launched a challenge to support people with this serious disease. . A 10 km run was carried out during the SSQ Lévis marathon in order to raise awareness and educate the population about this disease.

Thanks to donations from the public and various partners including Bayer Canada, among others, we are proud to announce that we have raised the sum of $ 7,044. The sums raised were donated to the Pulmonary Hypertension Research Group Fund of the IUCPQ Foundation, with the aim of advancing research and developing future therapies in addition to offering cutting-edge care to patients suffering from dementia. ‘HTAP.

2017 - VWR's customer appreciation evening

Quebec, Canada

A VWR’s customer appreciation evening has been taken June 12th 2017 on Louis-Jolliet boat with supper and dance evening.